Plasma β-amyloid 1-40 is associated with the diffuse small vessel disease subtype

Stroke

Volumn 40, Issue 10, 2009, Pages 3197-3201

  Gomis, Meritxell ^a   Sobrino, Tomás ^b   Ois, Angel ^c   Millán, Mònica ^a   Rodríguez Campello, Ana ^c   De La Ossa, Natalia Pérez ^a   Rodríguez González, Raquel ^b   Jiménez Conde, Jordi ^c   Cuadrado Godia, Elisa ^c   Roquer, Jaume ^c   Dávalos, Antoni ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

Acute stroke; Beta amyloid protein; Leukoaraiosis; Small vessel disease

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; LABORATORY TEST; LEUKOARAIOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ACUTE DISEASE; AGED; AMYLOID BETA-PROTEIN; ARTERIOLES; BRAIN INFARCTION; CAUSALITY; CEREBRAL ARTERIES; COHORT STUDIES; DEMENTIA, VASCULAR; ENDOTHELIAL CELLS; FEMALE; HUMANS; LEUKOARAIOSIS; MALE; MICROCIRCULATION; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS;

EID: 70349666996     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.559641     Document Type: Article

References (34)

1. Boiten J, Lodder J, Kessels F. Two clinically distinct lacunar infarct entities? A hypothesis. Stroke. 1993;24:652-656.
2. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28:652-659.
3. Fisher CM. Capsular infarcts: the underlying vascular lesions. Arch Neurol. 1979;36:65-73.
4. O'Sullivan M, Lythgoe DJ, Pereira AC, Summers PE, Jarosz JM, Williams SC, Markus HS. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology. 2002;59:321-326.
5. Terborg C, Gora F, Weiller C, Röther J. Reduced vasomotor reactivity in cerebral microangiopathy: a study with near infrared spectroscopy and transcranial Doppler sonography. Stroke. 2000;3:924-929.
6. Hassan A, Hunt BJ, O'Sullivan M, Parmar K, Bamford JM, Briley D, Brown MM, Thomas DJ, Markus HS. Markers of endothelial dysfunction in lacunar infarction and ischemic leukoaraiosis. Brain. 2003;126: 424-432.
7. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741-766.
8. Levy-Lahad E, Bird TD. Genetic factors of Alzheimer's disease: a review of recent advances. Ann Neurol. 1996;40:829-840.
9. Vinters HV, Wang ZZ, Secor DL. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol. 1996;6:179-195.
10. Greenberg SM, Rebeck GW, Vonsattel JPV, Gomez-Isla T, Hyman BT. Apolipoprotein E e4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995;38:254-259.
11. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fisher E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci. 1999;2:157-161.
12. Zhang F, Eckman C, Younkin S, Hsiao KK, Iadecola C. Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J Neurosci. 1997;17:7655-7661.
13. Niwa K, Carlson GA, Iadecola C. Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab. 2000;20:1659-1668.
14. Van Dijk EJ, Prins ND, Veermer SE, Hofman A, van Duijn CM, Koudstaal PJ, Breteler MMB. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol. 2004;55:570-575.
15. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglierie T, Rosand J, Growdon JH, Greenberg SM. Plasmaβ-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66:23-29.
16. Ois A, Cuadrado-Godia E, Jiménez-Conde J, Gomis M, Rodríguez-Campello A, Martínez-Rodríguez JE, Munteis E, Roquer J. Early arterial study in the prediction of mortality after acute ischemic stroke. Stroke. 2007;38:2085-2089.
17. Adams HP, Jr., Bendixen BH, Kapelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III; TOAST Investigators. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
18. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH Stroke Scale. Arch Neurol. 1989;46:660-662.
19. Fazekas Franz, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149:351-356.
20. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol. 1998;44:17-26.
21. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Youkin LH, Petersen RC, Youkin SG. Association of low plasma Aβ1-42/Aβ1-40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64: 354-362.
22. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60:958-964.
23. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR. Serum creatinine levels correlate with plasma amyloid beta protein. Alzheimer Dis Assoc Disord. 2002;16:187-190.
24. Khan U, Porteous L, Hassan A, Markus HS. Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry. 2007;78:702-706.
25. Markus SH. Genes, endothelial function and cerebral small vessel disease in man. Exp Physiol. 2007;93:121-127.
26. Gomis Cortina M, Rodríguez-Campello A, Jiménez-Conde J, Ois A, Voustianiouk A, Téllez MJ, Cuadrado E, Roquer J. Monocyte count is an underlying marker of lacunar subtype of hypertensive small vessel disease. Eur J Neurol. 2008;15:671-676.
27. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, Esteves F, Wharton SB, Shaw PJ, O'Brien JT, Ince PG; MRC Cognitive Function and Ageing Neuropathology Study Group. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke. 2006;37:1391-1398.
28. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and haemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke. 2005;36:1410-1414.
29. Khan U, Hassan A, Vallance P, Markus HS. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke. 2007;38:411-413.
30. van Dijk EJ, Prins ND, Hofman A, van Duijn CM, Koudstaal PJ, Breteler MMB. Plasmaβ amyloid and impaired CO2-induced cerebral vasomotor reactivity. Neurobiol Aging. 2007;28:707-712.
31. Wardlaw JM, Sandercock PAG, Dennis MS, Starr J, Kalimo H. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke. 2003;34:806-812.
32. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Ashe KH, Carlson GA, Iadecola C. Abeta 1-40-related reduction in functional hyperaemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A. 2000;97:9735-9740.
33. Lee PH, Bang OY, Hwang EM, Lee JS, Joo US, Mook-Jung I, Huh K. Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. J Neural Transm. 2005;112:1371-1379.
34. Bennett SAL, Pappas BA, Stevnes WD, Davidson CM, Fortin T, Chen J. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging. 2000;21:207-214.